Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Kidney Cancer

Brielle Benyon
Checkpoint inhibitors are moving into the treatment realm of renal cell carcinoma; however, questions still remain.
Katie Kosko
Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.
Targeted drugs are controversial in early-stage kidney cancer, but play a more important role in treating advanced disease.
Katie Kosko
More than 20 percent of patients with non–clear cell renal cell carcinoma (RCC) had a germline mutation, of which half had the potential to direct systemic therapy.
Katie Kosko
Experts at Roswell Park Comprehensive Cancer Center discovered a way to assess if a kidney tumor is benign or malignant, potentially sparing many from having to undergo surgery.
Kristie L. Kahl
The National Comprehensive Cancer Network updated its Clinical Practice Guidelines to add two new options for the frontline treatment of patients with kidney cancer.
Jason Harris
Immunotherapy pioneers James P. Allison, Ph.D., and Tasuku Honjo, M.D., Ph.D., have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.
Sandy Liu, MD, reviews the current challenges and recent advances in the treatment of renal cell carcinoma, or kidney cancer, as well as what she looks most forward to in the coming years.
Sandy Liu, MD, offers practical advice for patients undergoing treatment for renal cell carcinoma, or kidney cancer, regarding self-education, self-advocacy and adherence to therapy.
Sandy Liu, MD, outlines the available second-line therapeutic options for renal cell carcinoma, or kidney cancer, as well as what factors she considers when selecting from agents in this setting.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other